AFP and hepatocellular carcinoma: The most benefited group from the combination of the two biomarkers was intermediate (BCLC‐B) stage HCC cirrhotic patients, as in this group the diagnostic accuracy of each biomarker separately was moderate or good (AUROC 86.4% for AFP and 79.5% for PIVKA‐II) and became excellent (AUROC 92.4%) when the combination was used.